Verseon Corporation (“Verseon” or the “Company”)

Additional Listing and Total Voting Rights

Verseon, a technology-based pharmaceutical company, announces that on 8 September 2016, Dr. Thomas Hecht, Non-Executive Chairman of the Company, has been issued restricted stock units ("RSUs") that relate to payment of his Director's fees in the form of restricted stock. Dr. Hecht's restricted stock grant totals 28,037 Common Shares and is calculated by reference to the closing price on 8 September 2016 of the Company's common shares in USD, being $2.14. The RSUs vest quarterly in equal proportions over a one year period starting from 29 April 2016 and accordingly 7,009 RSUs have now vested.

The Company announces that application has been made for 7,009 new Common Shares of par value $0.001 each (the "Common Shares") to be admitted to trading on AIM pursuant to regularly scheduled vesting of the restricted stock units (the "Issuance") to Dr. Hecht. Following Admission, Dr. Hecht will hold 24,300 Common Shares, representing 0.016% of the Company's issued share capital.

The 7,009 new Common Shares issued pursuant to the Issuance will rank pari passu with the Company's existing Common Shares and admission to trading on AIM is expected to take place on 16 September 2016 ("Admission").

Total Voting Rights

Following Admission, the issued share capital of the Company will consist of 151,395,775 Common Shares. The Company does not hold any shares in treasury. Therefore the total number of Common Shares in the Company with voting rights will be 151,395,775. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.